1. Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter's Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1 Increased Nanotechnology in Developing Antiviral Agents
4.1.2 Technical breakthroughs in the development of antivirals
4.1.3 Increasing Unmet Needs and Population Growth
4.2 Restraints
4.2.1 High Risk of Failure and Government Firmness
4.2.2 Increasing Market for Generics
4.2.3 Lack of a widespread antiviral to treat multiple viral infections
4.3 Opportunities
4.3.1 Access to Antiviral Drugs in Pharmerging Markets
4.3.2 Increasing Need for Broad-Spectrum Drugs
4.4 Challenges
4.4.1 High cost of developing drugs
4.4.2 Increasing usage of natural products for the development of Antiviral drug
5. The Middle East & Africa Antiviral Drugs Market - By Therapeutic Area
5.1 Influenza Therapeutics Market
5.2 Herpes Therapeutics Market
5.3 Hepatitis Therapeutics Market
5.4 HIV/AIDS Therapeutics Market
6. The Middle East & Africa Antiviral Drugs Market - By Type
6.1 Genetics
6.2 Branded
7. The Middle East & Africa Antiviral Drugs Market - By Country
7.1.Introduction
7.2. Middle East
7.3. Africa
8. Company Profiles
8.1 Schering-Plough
8.2 Roche Holding AG
8.3 Merck & Co
8.4 MedImmune
8.5 AstraZeneca
8.6 Johnson & Johnson
8.7 GlaxoSmithKline
8.8 Gilead
8.9 Bristol-Myers-Squibb
8.10 Abbott
8.11 Pfizer
8.12 Aurobindo Pharma
8.13 Mylan N.V.
8.14 Cipla
8.15 Novartis International AG
9. North America Antiviral Drugs Market - Competitive Landscape
9.1 Market Share Analysis
9.2 Strategies Adopted by top companies
9.3 Mergers, Acquisitions, Collaborations & Agreements
10. Market Insights
10.1 Insights of Industry Experts
10.2 Investment Opportunities
10.3 Analyst Opinion
11. Appendix
11.1 List of Tables
11.2 List of Figures
